SELLAS (NASDAQ: SLS) Cancer Vaccine Cuts Death Risk 41% in Pivotal AML Trial - Stock Soars with Triple Digit Gains
SELLAS Life Sciences (NASDAQ: SLS) reported positive results from its Phase 3 REGAL trial, showing a 41% reduction in death risk for AML patients using its cancer vaccine, galinpepimut-S. The stock surged 170.42% to $20.20 on high volume. SELLAS plans to discuss accelerated FDA filing for the vaccine in 2027.
How this was made

The 30-second read
Why it matters
The disclosed hazard ratio, p-value, and median OS comparison represent a material clinical milestone, and the stated plan to discuss accelerated filing with the FDA and prepare a BLA for H1 2027 creates a concrete near-to-medium term catalyst path.
Market read
Traders have a fresh, company-specific catalyst: pivotal OS-positive Phase 3 topline results and an accelerated regulatory filing timeline, supporting immediate repricing and watch for follow-on conference/publication details.
What to watch
The article does not provide details on secondary endpoints, durability beyond median OS, or manufacturing/CMC readiness for accelerated filing, which can temper follow-through.
Background
SELLAS is a late-stage biopharmaceutical company developing WT1-targeted immunotherapies; REGAL is a pivotal Phase 3 trial in AML patients in second remission who are ineligible for or unable to undergo allogeneic stem cell transplantation.
Ticker impact
SELLAS reported positive topline Phase 3 REGAL results for galinpepimut-S in AML, meeting the OS primary endpoint with a 41% death-risk reduction vs BAT.
Likely further upside pressure as traders price in accelerated BLA timing and the magnitude of the OS benefit.
The article discloses statistically significant OS improvement (HR 0.59, p=0.035), favorable safety, and a stated intent to pursue accelerated filing with BLA preparations for H1 2027.
Market effects
Reinforces investor appetite for late-stage immunotherapy and WT1-targeted vaccine platforms in AML maintenance settings.
Primarily US biotech sentiment, with potential spillover to other AML-focused names on trial-readthrough expectations.
Limited direct global macro linkage; mainly affects global biotech risk appetite for AML immunotherapies.
Counterpoint
Topline OS results may face volatility as investors wait for full secondary endpoint details, subgroup analyses, and FDA feedback on the accelerated pathway.
Key entities
- companySELLAS Life Sciences Group, Inc.
Sponsor of the pivotal Phase 3 REGAL trial evaluating galinpepimut-S (GPS) in AML maintenance therapy.
- druggalinpepimut-S (GPS)
WT1-targeted immunotherapeutic cancer vaccine evaluated as maintenance monotherapy in REGAL.
- clinical_trialREGAL trial
Pivotal randomized Phase 3 study in AML second remission patients comparing GPS vs investigator’s choice of best available treatment.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory authority SELLAS plans to engage with regarding an accelerated filing strategy and BLA preparations.

